Moderna, Inc. News
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
see moreModerna, Inc. Market News
5d
Moderna Falls After FDA Memo on Pediatric Risk
- A leaked internal FDA memorandum proposing tougher vaccine approval standards and flagging potential pediatric myocarditis deaths rattled investors this week. Moderna shares fell sharply, dragging other vaccine names lower and raising questions about near-term regulatory hurdles for mRNA-based products.
12d
Moderna Shorted Heavily; $140M Backs Norwood Build
Recent reporting shows Moderna has become one of the most heavily shorted large-cap names while simultaneously committing $140 million to complete a domestic mRNA manufacturing site in Norwood. This article explains the short-interest dynamics, the strategic manufacturing investment, and how these developments affect MRNA stock.
19d
Moderna Boosts Liquidity; Q3 Revenue Pressures Q4!
Moderna secured a $1.5B non-dilutive credit facility, committed $140M to complete U.S. mRNA manufacturing, and reported a Q3 revenue decline with narrowed full-year guidance. These concrete actions strengthen liquidity and operational control but leave near-term revenue and profitability challenges that investors should weigh against upcoming clinical and commercial catalysts.
26d
Moderna Hits Turbulence: Q3 Results, CMV Cut, Vote
Moderna's recent week brought a mixed signal: a Q3 revenue beat but narrower guidance, termination of the CMV program, and a shareholder vote on an option exchange that could reduce dilution. Analysts remain cautious while institutional moves show both trimming and new interest.
07 Nov at 10:14
Moderna Gains FDA Nod; US Cancels $766M Flu Deal!!
Moderna won FDA approval for its next‑generation COVID vaccine mNEXSPIKE while the U.S. government simultaneously cancelled roughly $766M in bird‑flu vaccine contracts — a one‑two punch that produced mixed signals for MRNA stock, combining immediate commercial upside with a loss of government funding and political headwinds.